Regulatory news / Area HIV
Update: September 2023 - Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV
![Immagine News](/media/xuhk5yjv/immagine-regulatory-news.png?anchor=center&mode=crop&width=722&height=442)
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV has been updated as follow:
September 14, 2023
Mycobacterium tuberculosis
- Added recommendations for dolutegravir- and raltegravir-based antiretroviral (ARV) regimens in the context of tuberculosis (TB) disease for children >20 kg and <20 kg, respectively.
- Added references to American Academy of Pediatrics (AAP) guidance that recommends interferon-gamma release assays (IGRAs) to diagnose latent tuberculosis infection (LTBI) in children ≥2 years old.
- Added recommendations that children ≥2 years old with HIV infection who are receiving ARV regimens with acceptable drug-drug interactions with rifapentine can receive the 12-dose isoniazid-rifapentine LTBI treatment regimen.
Grazie per il tuo feedback!